The key findings of the paper include:
A cost savings of 21% - or approximately $36 million – over five years for the patient cohort treated with MT+V-tPA in Australia in 2021 (n=2194) compared to IV-tPA alone.
Sub-analysis conducted with 90-year-old patients still showed an estimated saving of $24.9m over 5 years (so it is still economically beneficial to treat elderly stroke patients with MT)
Each MT procedure performed delivers approximately $3280 in annual health system savings per patient.
The majority of these savings (78%) are generated within the first year, largely attributable to reduction in overall costs to 90 days.
